AKT1 and cancer: The pan-cancer NGS panel selected should, at a minimum, cover all actionable genomic biomarkers in NSCLC as recommended by Cancer Care Ontario [5], as well as other relevant biomarkers that may inform management decisions (e.g., TP53 alterations) and relevant genomic biomarkers for other tumour sites (e.g., ESR1 and AKT pathway genes for breast cancer).